Otsuka Ramps Up Its Antibody Game with $430M Visterra Acquisition

Otsuka Pharmaceutical is expanding its pipeline and U.S. reach with an agreement to acquire Waltham, MA, clinical-stage drug developer Visterra for $430 million in cash.